Chronic and complex wounds represent a substantial clinical and economic burden, affecting more than 6.5 million individuals in the United States and accounting for annual healthcare expenditures exceeding $25 billion. These wounds, including those arising from trauma such as blast and burn injuries, frequently involve multiple tissue types—e.g., skin, bone, and nerve—and are often associated with delayed or incomplete closure. In certain severe trauma populations, complications such as heterotopic ossification, characterized by abnormal bone formation within soft tissue, are observed at elevated incidence. More broadly, recalcitrant wounds are characterized by impaired healing dynamics, including persistent inflammation, fibrosis, and aberrant tissue regeneration. There are barriers to effective recovery because current standards of care have several critical limitations. Most therapies are “reactive” rather than “proactive” and they fail to adapt to the wound’s shifting physiological state, such as fluctuating pH or oxygen levels. Conventional devices use rigid or semi-rigid components, and this mismatch does not conform to contoured or mobile areas like the heel or joints. Moreover, semi-flexible electronics often lose contact during patient movement, and this inconsistent contact leading to sub-therapeutic dosing and persistent inflammation. Bridging this gap requires conformal, bio-integrated systems capable of sustained contact and autonomous, responsive therapeutic delivery to overcome the stagnant healing dynamics of recalcitrant wounds.